AzTrials
AzTrials

Non-metastatic Castration-resistant Prostate CancerPhase 4NCT05348876

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

A Phase 4 study testing Darolutamide (Nubeqa, BAY1841788) in people with Non-metastatic Castration-resistant Prostate Cancer, run by Bayer at 25 sites in India.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called… Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Darolutamide (Nubeqa, BAY1841788)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
25 sitesIndia
Study dates
3 Aug 2022to 29 Apr 2027
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Capable of giving signed informed consent.
  • Participant must be male aged ≥ 18 years.
  • Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
  • Castration resistance, demonstrated by:
  • a minimum of 3 rising PSA values while the participant is on continuous ADT (started at least 4 weeks prior to the PSA measurement or, PSA measured at least 4 weeks after bilateral orchiectomy) and
  • the interval between each PSA measurement must be ≥ 1 week, and
Show all 14Show fewer
  • the PSA value at screening must be ≥ 1.0 ng/mL (1.0 μg/L). To confirm this eligibility criterion, it is acceptable for 2 out of the 3 PSA measurements to be taken during the 28-day screening period (after participant has signed consent), provided the measurements are ≥ 1 week apart. In this case, the last PSA value should be recorded as the screening value.
  • Castrate level of serum testosterone (< 1.7 nmol/L [50 ng/dL]) on gonadotropin releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy. Participants who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.
  • PSA doubling time (PSADT) of ≤ 10 months.
  • Eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1.
  • Estimated glomerular filtration rate (eGFR) > 15 mL/min/1.73 m^2.
  • Blood counts at screening: hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥ 1500/μL (1.5 × 109/L), platelet count ≥ 100,000/μL (100 ×109/L) (participant must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).
  • Screening values of serum alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN), total bilirubin (TBL) ≤ 1.5 × ULN (except participants with a diagnosis of Gilbert's disease), creatinine ≤ 2.0 × ULN.
  • Sexually active participants, unless surgically sterile, must agree to use a male condom plus partner use of a contraceptive method with a failure rate of <1% per year, and refrain from sperm donation during the study treatment and for 1 week after the last dose of study treatment. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Who cannot join

  • History of metastatic disease at any time or presence of detectable metastases by investigator assessment within 42 days prior to start of study treatment based on standard medical imaging, i.e., computed tomography/ magnetic resonance imaging (CT/MRI) and bone scan. (Lesions seen on prostate-specific membrane antigen /positron emission tomography (PSMA/PET) scan that are not detected on standard imaging do not exclude participation.) Presence of pelvic lymph nodes < 1.5 cm in short axis below the aortic bifurcation is allowed.
  • Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer.
  • Acute toxicities of prior treatments and procedures not resolved to common terminology criteria for adverse events (CTCAE) v.5.0 grade ≤ 1 or baseline before first dose of study treatment.
  • Severe or uncontrolled concurrent disease, infection, or co-morbidity that, in the opinion of the investigator, would make the participant inappropriate for enrollment.
  • Known hypersensitivity to the study treatment or any of its ingredients.
  • Major surgery within 28 days before first dose of study treatment.
Show all 31Show fewer
  • Any of the following within 6 months before first dose of study treatment: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association Class III or IV.
  • Uncontrolled hypertension as indicated by a systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg at screening despite medical management. Participants with hypertension can enroll provided BP is stable and controlled by anti-hypertensive treatment.
  • End-stage renal disease (eGFR < 15 mL/min/1.73 m^2).
  • Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥ 5 years ago and from which the participant has been disease-free.
  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
  • Unstable active viral hepatitis with a need for treatment.
  • Known human immunodeficiency virus (HIV) infection with any of the following (Note: HIV testing is not required unless mandated by local authority):
  • CD4+ T-cell (CD4+) count of less than 350 cells/μL
  • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months
  • On established antiretroviral therapy for less than 4 weeks
  • Presenting with a viral load of more than 400 copies/mL prior to enrollment
  • On antiretroviral therapy or prophylactic antimicrobials that are expected to cause significant drug-drug interactions or overlapping toxicities with study treatment and cannot be changed to alternative agents.
  • Any condition that, in the opinion of the investigator, would impair the participants' ability to comply with the study procedures or study treatment (e.g., unable to swallow study treatment).
  • Unwilling or unable to comply with all protocol-required visits and assessments or comply with study requirements.
  • Prior treatment with:
  • Second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, darolutamide, proxalutamide, etc)
  • Other investigational AR inhibitors
  • Cytochrome P450 (CYP17) enzyme inhibitors (such as oral ketoconazole, abiraterone acetate, TAK-700, etc).
  • Use of first-generation AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before first dose of study treatment.
  • Use of estrogens or 5-α reductase inhibitors (finasteride, dutasteride) within 28 days before first dose of study treatment.
  • Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment completed > 2 years before first dose of study treatment.
  • Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before first dose of study treatment.
  • Radiation therapy (external beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 12 weeks before first dose of study treatment.
  • Treatment with an osteoclast-targeted therapy (bisphosphonate or denosumab) to prevent skeletal-related events within 4 weeks before first dose of study treatment. Participants receiving osteoclast-targeted therapy to prevent bone loss at a dose and schedule indicated for osteoporosis may continue treatment at the same dose and schedule.
  • Treatment with any investigational drug within 28 days before first dose of study treatment.

Trial locations and contacts

25 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Bayer Clinical Trials Contact contact

(+)1-888-84 22937

clinical-trials-contact@bayer.com

25 sites in 1 country

India25 sites, 8 recruiting

  • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation

    Amravati, Maharashtra, 444605

    Completed

  • Bangalore Medical College and Research Institute (BMCRI) - Victoria Hospital

    Bangalore, Punjab, 560001

    Terminated

  • KLES Dr. Prabhakar Kore Hospital & Medical Research Centre

    Belagavi, Karnataka, 590010

    Withdrawn

  • HCG Oncology Center

    Bengaluru, Karnataka, 560027

    Completed

  • Fortis Hospital Bangalore

    Bengaluru, Karnataka, 560076

    Terminated

  • All India Institute of Medical Sciences

    Bhubaneswar, Odisha, 751019

    Recruiting

  • Post Graduate Institute of Medical Education and Research

    Chandigarh, Uttar Pradesh, 160012

    Withdrawn

  • Erode Cancer Centre

    Erode, Tamil Nadu, 638012

    Terminated

  • Jawaharlal Institute Of Postgraduate Medical Education and R

    Gorimedu, Puducherry, 605006

    Completed

  • MNJ Institute of Oncology & Regional Cancer Centre

    Hyderabad, Telangana, 500004

    Terminated

  • Apollo Research Foundation

    Hyderabad, Telangana, 500096

    Completed

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, Rajasthan, 302017

    Completed

  • Amrita Institute of Medical Sciences

    Kochi, Kerala, 682041

    Recruiting

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, West Bengal, 700094

    Recruiting

  • Dayanand Medical College & Hospital

    Ludhiana, Punjab, 141001

    Withdrawn

  • Tata Memorial Hospital

    Mumbai, Maharashtra, 400012

    Recruiting

  • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)

    Nadiād, Gujarat, 387001

    Completed

  • Dr. RML Hospital & PGIMER

    New Delhi, National Capital Territory of Delhi, 110001

    Completed

  • Rajiv Gandhi Cancer Institute & Research Centre

    New Delhi, National Capital Territory of Delhi, 110085

    Recruiting

  • Surat Institute of Digestive Sciences

    Surat, Gujarat, 395002

    Terminated

  • Regional Cancer Centre - Thiruvananthapuram

    Thiruvananthapuram, Kerala, 695011

    Recruiting

  • Mahamana Pandit Madan Mohan Malviya Cancer Centre

    Varanasi, Uttar Pradesh, 221005

    Recruiting

  • MVR Cancer Centre and Research Institute

    Vellalasseri, Kerala, 673601

    Recruiting

  • HCG-City Cancer Centre

    Vijayawada, Andhra Pradesh, 520004

    Terminated

  • King George Hospital

    Visakhapatnam, Andhra Pradesh, 530002

    Terminated

Other trials in India

About this study

Official title: A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors.

In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant).

Read more

Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development.

Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body.

The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate.

Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition to ADT are already available, but this study had no Indian patients and was not conducted in India.

Therefore, the main purpose of this study is to learn how safe darolutamide is when taken in addition to ADT in Indian participants with high-risk nmCRPC.

To answer this question, the researchers will collect all medical problems the participants have that arise during the study and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE). The following information regarding safety of darolutamide will be collected during the study:

  • the number and severity of AEs that are non-serious or serious
  • the number of participants who have to permanently stop the treatment due to AEs
  • the number of participants who have to change the amount of study drug taken due to AEs

AEs can be:

  • abnormal results of laboratory tests, physical examinations, or heart health examinations using ECG (detects heart problems by measuring the electrical activity generated by the heart as it contracts).
  • relevant changes in vital signs
  • relevant changes of the participant's daily living abilities (ECOG performance status)

These results will then be compared with the results from the previous study to identify any differences for this group of participants.

In addition, researchers will collect and compare data on how well darolutamide worked under real world conditions in this group of participants.

All participants will take darolutamide as tablets by mouth twice a day. The participants will visit the study center at the start of the study, and then every 16 weeks until their cancer gets worse, they develop medical problems, they leave the study or until the study is terminated.

During the study, the study team will

  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • examine heart health using ECG
  • assess the participant's ECOG performance status
  • ask the participants questions about how they are feeling and what AEs they are having.

If the trial is stopped, participants may have the option to continue to receive darolutamide, provided they benefit from the treatment

Being tested
Darolutamide (Nubeqa, BAY1841788)
Keywords
Prostate cancer
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Darolutamide (Nubeqa, BAY1841788)Drug

    600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.

Study groups in NCT05348876
Study groupRoleWhat they receive
Darolutamide (BAY1841788)ExperimentalParticipants with high-risk nmCRPC will receive darolutamide.
Receives: Drug: Darolutamide (Nubeqa, BAY1841788)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity.

    Measured: Approximately 15 months.

  2. Number of participants with discontinuations of study treatment due to AEs

    Measured: Approximately 15 months

  3. Number of participants with dose modifications of study treatment due to AEs

    Measured: Approximately 15 months

  4. Number of participants with clinically significant abnormalities in laboratory parameters

    Measured: Approximately 15 months

  5. Number of participants with clinically significant electrocardiograms abnormalities

    Measured: Approximately 15 months

  6. Number of participants with clinically significant physical examination abnormalities

    Measured: Approximately 15 months

  7. Number of participants with clinically significant changes in vital signs

    Measured: From baseline to approximately 15 months

  8. Number of participants with changes in eastern cooperative oncology group (ECOG) performance status

    Measured: From baseline to approximately 15 months

Secondary outcomes (4)

  1. Prostate-specific antigen (PSA) percent change from baseline to 16 weeks

    Measured: From baseline to 16 weeks

  2. PSA maximum percent decline from baseline at any time on study treatment

    Measured: From baseline to approximately 15 months

  3. Time to initiation of first subsequent systemic antineoplastic therapy

    Measured: At approximately 15 months

  4. Time to initiation of first cytotoxic chemotherapy for prostate cancer

    Measured: At approximately 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2022
  2. Study start3 Aug 2022
  3. Primary completion29 Apr 2027 (estimated)
  4. Study completion29 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05348876
Sponsor's protocol ID
21707
Status last verified
Jul 2026
First submitted
21 Apr 2022
Last updated
6 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Darolutamide (Nubeqa, BAY1841788) in people with Non-metastatic Castration-resistant Prostate Cancer, run by Bayer at 25 sites in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 25 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Bayer Clinical Trials Contact ((+)1-888-84 22937, clinical-trials-contact@bayer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity. (time frame: Approximately 15 months.). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05348876.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in